Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer

Citation
Dw. Knapp et al., Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer, CANC CHEMOT, 46(3), 2000, pp. 221-226
Citations number
26
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER CHEMOTHERAPY AND PHARMACOLOGY
ISSN journal
0344-5704 → ACNP
Volume
46
Issue
3
Year of publication
2000
Pages
221 - 226
Database
ISI
SICI code
0344-5704(200009)46:3<221:CVCCWP>2.0.ZU;2-S
Abstract
Purpose: More than 12,000 people are expected to die from invasive transiti onal cell carcinoma (TCC) of the urinary bladder each year in the United St ates. indicating that more effective therapy is needed. Drugs inhibiting cy clooxygenase (cox) have recently been found to have chemopreventive and ant itumor activity and may potentiate the effects of chemotherapy. The purpose of this study was to determine whether cisplatin combined with the cox-inh ibitor piroxicam would induce remission more frequently than cisplatin alon e in a relevant animal model of human invasive TCC. Methods: Pet dogs with naturally occurring, histopathologically confirmed, measurable TCC of the u rinary bladder were randomized to receive cisplatin (60 mg/m(2) i.v. every 21 days) or cisplatin (same dosage) combined with piroxicam (0.3 mg/kg oral ly every 24 h). Complete staging was performed prior to and at 6-week inter vals during therapy. Results: After eight dogs had been evaluated in each t reatment group, a significant difference in remission rate was noted (Fishe r's Exact test, P < 0.003). Tumor responses in the cisplatin/piroxicam grou p included two complete remissions (CR), four partial remissions (PR). two stable disease (SD, and no progressive disease (PD). Tumor responses to cis platin alone in eight dogs were no CR, no PR, four SD, and four PD. Six add itional dogs were treated with cisplatin/piroxicam, and in total 10 of 14 d ogs had remission (two CR, eight PR). Renal toxicity of cisplatin/piroxicam was frequent and dose limiting. Conclusions: Cisplatin:piroxicam induced r emission more frequently than cisplatin alone in a canine model of human in vasive TCC. Strategies to reduce renal toxicity need to be developed prior to evaluation of cisplatin/piroxicam in humans or general use of this treat ment in pet dogs.